Home
Clinical Resources Search
PQI: Telotristat Ethyl (Xermelo®) for the Management of Carcinoid Syndrome Diarrhea

Telotristat Ethyl (Xermelo®) for the Management of Carcinoid Syndrome Diarrhea

Download PQI pdf

Last Updated: November 29, 2023

By: Lisa Raff, PharmD, BCPS, BCOP

About this PQI

This PQI will review appropriate patient identification and management techniques to ensure optimal benefit from telotristat ethyl therapy.

More About This PQI

PQI in Action Articles:

Telotristat_XERMELO_Diarrhea pdf

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care.

Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Frequently Searched

Supported by

Telotristat Ethyl (Xermelo®) for the Management of Carcinoid Syndrome Diarrhea

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

PQI: Gedatolisib Combination Therapy for Locally Advanced or Metastatic Breast Cancer

PQI: Relacorilant (LIFYORLI) and Albumin-Bound Paclitaxel (Nab-Paclitaxel) for Platinum-Resistant Ovarian Cancer

PQI in Action: Inavolisib (Itovebi) Patient Management

PQI in Action: Revumenib (Revuforj) for the Management of Acute Leukemia

PQI in Action: Capivasertib (Truqap) Patient Management

PQI in Action: Sutimlimab-jome (Enjaymo) for the Management of Hemolysis in Cold Agglutinin Disease (CAD)

S11 E9: Keep Saying Yes: Living, Advocating, and Finding Purpose with Cancer

S11 E10: Fungi, Facts, and Cancer Care: Exploring Medicinal Mushrooms

S11 E8: The Future of Oncology

S11 E7: Your Health Story in One Place

Toolkit: Simplify CLL Tracking in Oncology Practices

Toolkit: Optimize CLL Care in Epic

Treatment Support Kit: Elranatamab

Treatment Support Kit: Bispecific (T-Cell Engager)

Treatment Support Kit: Zanidatamab-hrii

Treatment Support Kit: Avutometinib and Defactinib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Capecitabine

Octreotide

Lanreotide

PQI: Sacituzumab govitecan-hziy (Trodelvy®): Prophylaxis and Management of Adverse Events

Octreotide

Understanding Diarrhea During Cancer Treatment

PQI: Oncolytic Induced Diarrhea

Sorafenib

Trifluridine and Tipiracil

Olaparib

Regorafenib

PQI in Action: Telotristat Ethyl: Carcinoid Syndrome Diarrhea

PQI in Action: Telotristat Ethyl: Carcinoid Syndrome Diarrhea

PQI: Retifanlimab-dlwr in Combination with CARBOplatin + PACLItaxel for the First-Line Treatment of Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal

PQI: Ruxolitinib Extended Release for the Management of Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease

Rusfertide (Mimrylo)

Lirafugratinib (Lyrfigtu)